Loading
A phase 2 trial in triple-negative breast cancer, run by H. Lee Moffitt Cancer Center and Research Institute, now recruiting.
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT05528133 by H. Lee Moffitt Cancer Center and Research Institute, with a registry enrolment figure of 86 participants, started 2023-01-25 and due to reach its primary completion in 2028-05. Interventions recorded: Genomically Guided Radiation Therapy; Genomically Guided Radiation Therapy. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Confirmation of Triple Negative (TN) breast cancer by tissue biopsy". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.